Cancer in Dogs: Which Lumps Need a Needle Aspirate and Why Waiting Fails

A lump appears on your dog's flank one Tuesday. It is soft, moves under your fingers, and does not seem to bother him. The instinct is to monitor it. That instinct is wrong often enough that veterinary oncologists have a name for the pattern: the wait-and-see delay, and it is one of the most common reasons dogs present with late-stage mast cell tumours.

Canine tumours do not follow the rules people assume. Mast cell tumours, the most common malignant skin tumour in dogs, accounting for roughly 20 percent of all canine skin tumours according to the American College of Veterinary Internal Medicine, can feel soft and moveable. They can shrink and swell on their own because mast cells release histamine, which causes local inflammation that fluctuates. A tumour that appears to be getting smaller is not necessarily resolving. It may be degranulating, which is a process that itself carries systemic risk.

Lipomas, the genuinely benign fatty lumps that most owners are hoping for, feel nearly identical to soft-tissue sarcomas in early presentation. Soft-tissue sarcomas grow along fascial planes, which means they can appear well-defined and moveable at the surface while extending deep into muscle tissue in a way that is invisible to touch. By the time a soft-tissue sarcoma becomes visibly large or fixed, surgical margins are already compromised.

The biological fact is this: location, texture, and growth rate are unreliable diagnostic criteria. A needle aspirate is not.

A fine needle aspirate, or FNA, takes less than a minute in most dogs and requires no sedation. A 22 to 25 gauge needle is inserted into the mass, cells are drawn into the syringe, and those cells are spread on a glass slide for cytological examination. The procedure has no meaningful recovery time and carries negligible risk of seeding tumour cells along the needle tract in the vast majority of canine tumour types.

Cytology from an FNA can distinguish between round cell tumours, which include mast cell tumours, lymphoma, histiocytic tumours, and transmissible venereal tumour, and mesenchymal or epithelial tumours. Round cell tumours exfoliate well, meaning they shed cells readily onto the slide, and a skilled clinical pathologist can often give a diagnosis from cytology alone. Mast cell tumours in particular are cytologically distinctive: the purple granules inside the cells are visible under standard staining.

Mesenchymal tumours, including soft-tissue sarcomas and nerve sheath tumours, exfoliate poorly. An FNA may return low cellularity and an inconclusive result. That result is still information. It tells the clinician that histopathology of a full biopsy is the next step, not continued observation.

Certain presentations make an FNA the same-day priority, not a discussion for the next routine appointment.

Any lump on a dog over seven years old warrants cytology promptly. Canine cancer rates rise sharply with age, and the same mass that might have been a reactive lymph node in a three-year-old dog is a different statistical proposition in a ten-year-old.

Lumps in the groin, axilla, or popliteal region, the hollows behind the knees, are often lymph nodes. An enlarged lymph node is not a skin lump; it is a sign that the lymphatic system is responding to something, and lymphoma is the condition that cannot afford a six-week watch period. Multicentric lymphoma in dogs can progress from Stage I to Stage IV in weeks.

Any mass on the digits, particularly on or near the nail bed, carries a high prior probability of subungual melanoma or squamous cell carcinoma, both of which are locally aggressive and metastasise early. The same applies to masses on the lips and gums.

Rapidly growing lumps, those that double in size over two to four weeks, regardless of location, need cytology before the next appointment slot opens. Growth rate is one of the few surface observations that carries genuine diagnostic weight, and fast growth in any direction is not reassuring.

Canine cancer is not distributed evenly across breeds, and knowing your dog's genetic predisposition changes how aggressively you should pursue early cytology.

Boxers and Pugs have among the highest rates of mast cell tumour of any breed. A soft moveable lump on a Boxer is a mast cell tumour until cytology says otherwise. Flat-coated Retrievers carry an elevated lifetime risk of histiocytic sarcoma, a tumour that is almost uniformly fatal and that progresses rapidly. Golden Retrievers have a lifetime cancer incidence estimated at over 60 percent in North American populations, with hemangiosarcoma and lymphoma among the most common causes of death. Bernese Mountain Dogs face similar hemangiosarcoma risk, as well as histiocytic sarcoma.

For these breeds, the threshold for requesting an FNA should be lower than the average dog, and owners should say so explicitly at appointments: name the breed risk, ask for cytology, and do not accept reassurance based on palpation alone.

The argument for monitoring a lump is that it avoids an unnecessary procedure. The argument against it is that the cost of being wrong is asymmetric. A benign lipoma watched for six weeks is still a benign lipoma. A mast cell tumour watched for six weeks may have moved from a Grade II, surgically curable tumour to a Grade III tumour with regional lymph node involvement, where the treatment protocol becomes chemotherapy and the prognosis changes substantially.

Surgical cure rates for canine mast cell tumours are high when the tumour is caught at a low grade with clean margins achievable. The same tumour at a higher grade, or with satellite lesions that developed during a watch period, is a different surgical and oncological problem. The needle aspirate costs a fraction of what one additional round of chemotherapy costs, and it costs nothing compared to the options that close when a window closes.

A veterinary oncologist or a general practice vet with a relationship with an external clinical pathology laboratory can process most FNA slides within 24 to 72 hours. If your vet recommends monitoring a new lump without cytology, it is reasonable to ask directly: what is the cytological reason to wait rather than aspirate now? The answer to that question, whatever it is, gives you information. The lump on its own does not.